Oryzon Genomics (MEX:ORYN) Total Liabilities: MXN485.42 Mil (As of Mar. 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics Total Liabilities?

Oryzon Genomics MEX:ORYN 31 Total Liabilities is MXN485.42 Mil as of Mar. 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100.

Oryzon Genomics's Total Liabilities for the quarter that ended in Mar. 2026 was MXN485.42 Mil.

Oryzon Genomics's quarterly Total Liabilities declined from Sep. 2025 (MXN624.84 Mil) to Dec. 2025 (MXN564.17 Mil) and declined from Dec. 2025 (MXN564.17 Mil) to Mar. 2026 (MXN485.42 Mil).

Oryzon Genomics's annual Total Liabilities declined from Dec. 2023 (MXN471.44 Mil) to Dec. 2024 (MXN470.36 Mil) but then increased from Dec. 2024 (MXN470.36 Mil) to Dec. 2025 (MXN564.17 Mil).

Oryzon Genomics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Total Liabilities Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 560.28 650.80 471.44 470.36 564.17

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 485.58 532.74 624.84 564.17 485.42
MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Oryzon Genomics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=333.448+(65.235+165.49
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=564.17

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3056.666-2492.493
=564.17

Oryzon Genomics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+485.422
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=485.42

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2938.068-2452.646
=485.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of MXN485.42 Mil mean?
Oryzon Genomics (MEX:ORYN) has a Total Liabilities of MXN485.42 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oryzon Genomics and its competitors.
Is Oryzon Genomics' Total Liabilities too high?
Oryzon Genomics' current Total Liabilities is MXN485.42 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Total Liabilities compare to VRTX and REGN?
Oryzon Genomics' Total Liabilities of MXN485.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oryzon Genomics and its competitors. Oryzon Genomics's current Total Liabilities is MXN485.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Total Liabilities of MXN485.42 Mil. The current Total Liabilities is MXN485.42 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Total Liabilities is MXN485.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price